EDX Medical Group (LSE:EDX), the Cambridge-based digital diagnostics developer, has launched full UK availability of its BC95 bowel cancer testing service.
The service combines three tests: an early-detection biomarker test, a hereditary genetic risk panel, and a faecal haemoglobin reference test aligned with current NHS practice.
Bowel cancer is the second most common cause of cancer deaths worldwide, with more than 46,000 people diagnosed annually in the UK and around 17,700 deaths a year, according to Bowel Cancer UK.
BC95 achieves sensitivities above 95% across stages 1 to 4 of the disease, the company said.
EDX Medical holds an exclusive UK agreement with South Korea's Genomictree for its EarlyTect epigenetic test, which detects methylation of the SDC2 gene, a biomarker frequently found in early-stage colorectal cancer tissue.
In a clinical study of 1,124 asymptomatic patients with a 1.8% disease incidence, the test showed 95% average sensitivity for stage 1-4 cancers and 89.1% sensitivity for very early-stage cases, stages 0-2.
It also detected pre-cancerous adenomatous polyps with 58.1% sensitivity.
The company said preliminary clinical evaluation, following a launch to clinicians, showed particular demand for the early-detection element.
"The BC95 bowel cancer testing service is an important contribution to detecting bowel cancer early", said chief executive Dr Mike Hudson.
News Intelligence what this means for the company
EDX Medical has moved its BC95 bowel cancer test to full UK commercial availability, following early clinician feedback that highlighted demand for the early-detection component. The service combines an epigenetic biomarker test (achieving 95% sensitivity for stage 1–4 cancers and 89.1% for very early stages), a hereditary risk panel, and a faecal haemoglobin test aligned with NHS practice, positioning EDX to capture demand in a market where bowel cancer causes over 17,700 UK deaths annually.
The launch expands EDX's addressable market in precision oncology beyond its existing Caris MI Profile distribution and corporate workplace screening agreements, but the announcement provides no revenue guidance, patient uptake targets, or NHS reimbursement status, investors will look for these material gaps to be filled before assessing commercial traction in a regulated diagnostic market.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
